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Aim: To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with
type 1 diabetes.
Methods: The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n= 243) were randomized to
Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose
target of 4.4–7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia
and change in body weight.
Results: Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference
0.13 % [95 % confidence interval (CI) −0.03 to 0.29]}. The annualized rate of confirmed (≤3.9 mmol/l) or severe hypoglycaemic events was 34 % lower
with Gla-300 than with Gla-100 at night [rate ratio 0.66 (95 % CI 0.48–0.92)] and 20 % lower at any time of day [24 h; rate ratio 0.80 (95 % CI 0.65–0.98)];
this difference was most pronounced during the first 8 weeks of treatment. Severe hypoglycaemia was infrequent. The basal insulin dose increased in both
groups (month 6 dose: Gla-300 0.35 U/kg/day, Gla-100 0.29 U/kg/day). A between-treatment difference in body weight change over 6 months favouring
Gla-300 was observed [LS mean difference −0.6 kg (95 % CI −1.1 to −0.0); p= 0.035]. Adverse event rates were comparable between the groups.
Conclusions: In Japanese adults with type 1 diabetes using basal plus mealtime insulin, less hypoglycaemia was observed with Gla-300 than with
Gla-100, particularly during the night, while glycaemic control did not differ.
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Introduction
Insulin-based therapy remains the mainstay of treatment for
type 1 diabetes worldwide, with most people receiving a com-
bination of basal plus mealtime insulin or continuous sub-
cutaneous insulin infusion [1–3]. The once-daily, long-acting
basal insulin analogue insulin glargine 100 U/ml [Gla-100
(Lantus®; Sanofi, Paris, France)] was licensed in Japan in 2003
[4] and has been shown to achieve glycaemic control simi-
lar to or greater than that of human neutral protamine Hage-
dorn (NPH) insulin [5,6], accompanied by numerically fewer
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mild-to-moderate hypoglycaemic events [5] and less severe
hypoglycaemia [6]. Nevertheless, despite the available treat-
ment options, >45 % of people with diabetes worldwide do
not achieve their glycated haemoglobin (HbA1c) targets [7–9].
There is considerable interest in further improving type 1 dia-
betes treatment with a basal insulin that maintains glycaemic
control while minimizing the risk of hypoglycaemia and allow-
ing flexibility of injection times [2,10,11]. Pharmacokinetic
(PK) and pharmacodynamic (PD) studies with new insulin
glargine 300 U/ml (Gla-300) indicate that it has the potential to
address these clinical needs [12–14]. In a single-dose study in
Japanese people with type 1 diabetes, Gla-300 showed more sta-
ble and prolonged PK and PD profiles compared with Gla-100,
with tight blood glucose control maintained for up to 36 h [14].
This was also observed in a European population [14] and is
consistent with the more stable and prolonged PK and PD
profiles observed at steady state with Gla-300 in a European
population [13].
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The phase IIIa EDITION programme has shown that
Gla-300 is as effective as Gla-100 in achieving glucose control
in multinational populations with type 1 or 2 diabetes [15–19]
without raising any safety concerns. In Western populations
with type 2 diabetes, it was shown that glycaemic control
was accompanied by a reduction in hypoglycaemia risk with
Gla-300 versus Gla-100 [15,17,19]. In a multinational type 1
diabetes population (EDITION 4), comparable glycaemic
control was observed, but with no difference in annualized
rates of hypoglycaemia, except during the first 8 weeks of
treatment, when the rate of nocturnal confirmed [≤3.9 mmol/l
(≤70 mg/dl)] or severe hypoglycaemia was lower with Gla-300
than with Gla-100 [16]. In addition, a study in people with
type 1 diabetes that used continuous glucose monitoring
showed more stable 24-h glucose levels and lower glucose
variability, with lower annualized rates of nocturnal confirmed
[<3.0 mmol/l (<54 mg/dl)] or severe hypoglycaemia with
Gla-300 than with Gla-100 [20]. In both of these studies in
type 1 diabetes, the same efficacy and safety was observed with
Gla-300, regardless of injection time (morning versus evening)
[16,20]. Gla-300 was licensed in the USA, Europe and Japan in
2015 (as Toujeo® in the USA and Europe and as Lantus® XR
in Japan). In the present study, we investigated the efficacy and
safety of Gla-300 versus Gla-100 in Japanese adults with type 1
diabetes already using basal and mealtime insulin.
Materials and Methods
Research Design
The EDITION JP1 study (NCT01689129) was a multicentre,
randomized, open-label, two-arm, parallel-group, phase III
study in Japanese participants with type 1 diabetes. The study
comprised a 2-week screening phase and a 6-month, main
treatment period, followed by a preplanned 6-month extension
period. The results from the main 6-month treatment period
are reported in the present paper. The protocol was amended
after study commencement to include an independent review
of all hypoglycaemic events reported as severe and/or as seri-
ous adverse events (SAEs) by a Severe Hypoglycaemia Review
Board to ensure consistency across the EDITION studies. The
appropriate ethics committees approved the study, which was
conducted in accordance with Good Clinical Practice [21] and
the Declaration of Helsinki [22]. Written informed consent
was obtained from all participants.
Participants
Participants were recruited as outpatients at 22 centres in
Japan. Adults ≥18 years with type 1 diabetes receiving basal
and mealtime insulin for ≥1 year with HbA1c ≥7.0 and ≤10.0
% (≥53 and ≤86 mmol/mol) at screening were included. Key
exclusion criteria were: unstable insulin dose (±20 % total
basal insulin dose) in the previous 30 days; use of premixed
insulin, human regular insulin as mealtime insulin and/or any
antihyperglycaemic drugs other than basal insulin and meal-
time rapid-acting insulin analogues within 3 months; use of an
insulin pump within 6 months; any contraindication for use of
insulin glargine as defined by the product labelling in Japan;
severe hypoglycaemia resulting in coma/seizures or hospital-
ization for diabetic ketoacidosis within 6 months.
Randomization and Masking
Participants were randomized (1 : 1) to Gla-300 or Gla-100,
stratified by HbA1c at screening visit [<8.0 or ≥8.0 % (<64 or
≥64 mmol/mol)]. Owing to differences between insulin injec-
tion devices and injection volumes, the study was open-label;
however, efficacy variables were assessed based on anonymized
samples at the central laboratory.
Interventions
Participants received once-daily subcutaneous injections of
Gla-300 [using a modified TactiPen® injector (Haselmeier
GmbH, Zürich, Switzerland)] or Gla-100 [using a SoloSTAR®
injector (Sanofi)], at the same time each evening (between
pre-dinner and bedtime). The initial daily dose of Gla-300
or Gla-100 was equal to the total daily basal insulin dose
on the day preceding the baseline visit for those previously
receiving Gla-100 (once or twice daily), NPH insulin or
insulin detemir once daily, or 20 % less for those previ-
ously receiving NPH insulin or insulin detemir more than
once daily. Gla-300 or Gla-100 was titrated to a fasting
(preprandial) self-monitored plasma glucose (SMPG) target
of 4.4–7.2 mmol/l (80–130 mg/dl). Basal insulin dose titration
was performed once weekly, and no more than every 3–4 days
when more frequent adjustments were required. Visits (either
by phone or on-site) were scheduled once weekly up to week
12, then on weeks 17, 22 and 26. Additional visits could be
scheduled to discuss dose adjustments if required. At the
discretion of the investigator, participants could be allowed
to adjust their basal insulin dose without prior consultation
with site personnel. The basal insulin dose was increased if
the median of the fasting (pre-breakfast) SMPG over the last
3 days was >7.2 mmol/l (>130 mg/dl) with no evidence of
relevant hypoglycaemia. Gla-300 and Gla-100 were increased
by >10 and 10 % of the daily dose, respectively, in ranges
of 1.5–4.5 and 1.0–4.0 U/day. If fasting (preprandial) SMPG
was <4.4 mmol/l (<80 mg/dl) or if relevant hypoglycaemia
occurred, the dose was reduced by 1.5 or 1.0 U/day for
Gla-300 and Gla-100, respectively, at the investigator’s discre-
tion. Upward titration was stopped for 1 week and the dose
decreased at the investigator’s discretion if fasting (preprandial)
SMPG was <3.3 mmol/l (<60 mg/dl) or an episode of severe
hypoglycaemia (requiring assistance) was reported without an
adequate explanation for the event (such as missing a meal
or heavy exercise). Participants continued mealtime insulin
during the study, administered according to approved labelling
in Japan and titrated to achieve glycaemic control after basal
insulin doses had been optimized; mealtime dose could be
reduced while basal insulin doses were increased to avoid
daytime hypoglycaemia.
Outcomes
The primary endpoint was change in HbA1c from base-
line to month 6. Secondary efficacy endpoints included
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change in laboratory-measured fasting plasma glucose (FPG),
pre-injection SMPG [measured directly before the time of basal
insulin administration; this could coincide with the time of an
eight-point SMPG measurement (i.e. bedtime), in which case
one value was to be recorded for both measures], mean overall
eight-point SMPG profiles (03:00 h, before breakfast, 2 h after
breakfast, before lunch, 2 h after lunch, before dinner, 2 h after
dinner, bedtime), change in daily basal insulin dose and daily
mealtime insulin dose from baseline to month 6. The percent-
ages of participants reaching HbA1c <7.0 % (<53 mmol/mol)
with and without experiencing hypoglycaemic events were
also examined. Exploratory efficacy endpoints included the
percentage of participants with laboratory-measured FPG
<5.6 mmol/l (<100 mg/dl) at month 6. All hypoglycaemic
events were recorded based on American Diabetes Associa-
tion definitions [23] according to the time of day that they
occurred [any time of day (24 h) or nocturnal (00:00–05:59 h)]
and by study period (full 6-month study period, baseline to
week 8 and week 9 to month 6). The categories included:
documented symptomatic hypoglycaemia [symptomatic events
with SMPG ≤3.9 mmol/l (≤70 mg/dl)]; asymptomatic hypo-
glycaemia [events without symptoms confirmed by SMPG
≤3.9 mmol/l (≤70 mg/dl)]; severe hypoglycaemia (events
requiring assistance from another person); confirmed or severe
hypoglycaemia (all documented symptomatic, asymptomatic
and severe events); probable symptomatic hypoglycaemia
(symptoms of hypoglycaemia without SMPG determina-
tion). The occurrence of hypoglycaemic events at a lower
<3.0 mmol/l (<54 mg/dl) threshold was also analysed.
Other clinical and safety measurements included body
weight, injection site reactions, hypersensitivity reactions and
other AEs.
Data Analysis and Statistics
A sample size of 240 participants (N= 120 for both groups)
was estimated to give 90 % power for the upper confidence
limit of the mean difference in change in HbA1c between treat-
ment groups not to exceed 0.4 % (4.4 mmol/mol), assuming
the standard deviation (s.d.) was 0.9 %, for a true difference of
0.0 %, and that all participants were evaluable. Non-inferiority
of Gla-300 versus Gla-100 was shown if the upper limit of the
two-sided confidence interval (CI) for the difference in mean
change in HbA1c versus baseline was lower than the predefined
non-inferiority margin of 0.4 % (4.4 mmol/mol).
Efficacy endpoints were analysed using the modified
intention-to-treat population (all randomized participants
who received ≥1 dose of study treatment, and had both
a baseline assessment and ≥1 post-baseline assessment
for any efficacy variable). Safety endpoints were analysed
descriptively using the safety population (all randomized
participants exposed to ≥1 dose of the study treatment).
Hypoglycaemia was analysed as the percentage of partic-
ipants experiencing ≥1 event and the number of events
per participant-year. Between-treatment differences in body
weight and annualized rates of hypoglycaemia were analysed




Eligible participants were randomized (N= 122, Gla-300;
N= 121, Gla-100) between October 2012 and October 2013
(Figure 1). All randomized participants received study treat-
ment. Baseline characteristics were not different between the
two groups (Table 1). The discontinuation rate was 4.1 % for
the Gla-300 group and 3.3 % for the Gla-100 group.
Glycaemic Control
At month 6, the mean HbA1c level had decreased by 0.30 %
(3.3 mmol/mol) with Gla-300 versus 0.43 % (4.7 mmol/mol)
with Gla-100 (Figure 2A and Table S1). The least squares (LS)
mean difference was 0.13 % [95 % confidence interval (CI)
−0.03 to 0.29], demonstrating non-inferiority of Gla-300 ver-
sus Gla-100. No between-treatment differences were observed
in change from baseline to month 6 in laboratory-measured
FPG (Table S1 and Figure 2B). The percentages of people
receiving Gla-300 and Gla-100 who achieved HbA1c <7.0 %
(<53 mmol/mol) were 15.6 % (19/122) and 20.0 % (24/120),
respectively (Table S1).
At month 6, SMPG was consistently lower at all time points
(demonstrated by average eight-point SMPG profiles) in the
Gla-300 group compared with baseline, whereas there was no
consistent trend in the Gla-100 group (Figure 3). At month 6,
mean pre-dinner SMPG was significantly lower with Gla-300
[8.4 mmol/l (151.7 mg/dl)] versus Gla-100 [10.0 mmol/l
(180.3 mg/dl); LS mean difference −1.6 (95 % CI −2.8 to −0.3)
mmol/l or −28.1 mg/dl (95 % CI −50.1 to −6.1)]. Glycaemic
control was notably better with Gla-300 than Gla-100 from
pre-dinner to bedtime at month 6 (Figure 3 and Table S1). At
month 6, average pre-injection SMPG was also significantly
lower with Gla-300 [9.3 mmol/l (166.8 mg/dl)] versus Gla-100
[10.3 mmol/l (185.8 mg/dl); LS mean difference −1.0 mmol/l
(95 % CI −1.8 to −0.3) or −18.5 mg/dl (95 % CI −32.0 to −5.0);
Figure 2C and Table S1].
Insulin Dose
The mean (s.d.) total insulin dose at month 6 was 0.79
(0.25) U/kg/day (basal 0.35 U/kg/day; mealtime 0.44 U/kg/day)
for the Gla-300 group and 0.74 (0.22) U/kg/day (basal
0.29 U/kg/day; mealtime 0.45 U/kg/day) for the Gla-100
group (Figure 2D). This corresponds to a mean (s.d.) total
insulin dose of 50.7 (20.4) U/day (basal 23.0 U/day; mealtime
28.0 U/day) for the Gla-300 group and 46.0 (17.6) U/day (basal
18.2 U/day; mealtime 27.8 U/day) for the Gla-100 group.
Hypoglycaemia
Hypoglycaemia was reported in 119 participants (4622 events)
in the Gla-300 group and in 118 participants (5696 events)
in the Gla-100 group. Overall hypoglycaemia rates were lower
with Gla-300 than with Gla-100 both at any time (24 h) and
during the night (00:00–05:59 h; Tables S2 and S3).
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• n = 14 due to
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 medical criteria
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Figure 1. Flow of participants through the main 6-month period of the EDITION JP 1 study [modified intention-to-treat (mITT) and safety populations].
Gla-100, insulin glargine 100 U/ml; Gla-300, insulin glargine 300 U/ml.
Confirmed or Severe Hypoglycaemia.
Hypoglycaemia at any time of day. The cumulative mean
number of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe
hypoglycaemic events per participant at any time (24 h) was
lower with Gla-300 than with Gla-100 throughout the study
(Figure 4A). Annualized rates of confirmed [≤3.9 mmol/l
(≤70 mg/dl)] or severe hypoglycaemia were lower with Gla-300
versus Gla-100 over 6 months (Figure 4B and Table S2). In addi-
tion, numerically fewer confirmed [<3.0 mmol/l (<54 mg/dl)]
or severe hypoglycaemic events were reported between base-
line and month 6 by Gla-300-treated participants (Figure 4E
and Table S2).
Almost all participants experienced confirmed [≤3.9 mmol/l
(≤70 mg/dl)] or severe hypoglycaemia during the study, with
no difference between treatment groups (Figure 4F and
Table S3). Fewer participants in the Gla-300 group than the
Gla-100 group experienced confirmed or severe hypoglycaemia
at the stricter <3.0 mmol/l (<54 mg/dl) threshold (Figure 4F
and Table S3).
Nocturnal hypoglycaemia. The cumulative mean num-
ber of nocturnal (00:00–05:59 h) confirmed [≤3.9 mmol/l
(≤70 mg/dl)] or severe hypoglycaemic events per participant
was lower with Gla-300 than with Gla-100 throughout the study
period (Figure 4C). The rapid increase during the last 8 days
of the main 6-month treatment period in the Gla-300 group
is an artefact caused by the very low number of participants
exposed to treatment during this time who experienced only
one event on each of days 187, 189 and 190. Annualized rates
were lower with Gla-300 than with Gla-100 at both thresholds
(Figure 4D and E and Table S2). Similarly, the percentage of
participants experiencing ≥1 nocturnal confirmed or severe
hypoglycaemic event over 6 months was lower with Gla-300
than with Gla-100 at both thresholds (Figure 4F and Table S3).
Distribution of Hypoglycaemia Over 24 h. The majority of hypo-
glycaemic events, regardless of category, occurred between
06:00 and 23:59 h (4155 and 5011 events with Gla-300 and
Gla-100, respectively). The annualized rate of confirmed
[≤3.9 mmol/l (≤70 mg/dl)] or severe events over 6 months was
not only similar or lower with Gla-300 versus Gla-100 during
the night, but also up to 14:59 h (Figure S1).
Other Hypoglycaemia Definitions. Similar results to those
described for confirmed or severe hypoglycaemia at both
thresholds were seen across other definitions of hypoglycaemia
(Tables S2 and S3). For both rates and risk of hypoglycaemia,
the reduction in favour of Gla-300 was more pronounced in
the first 8 weeks for all analysed definitions (Tables S2 and S3).
Severe Hypoglycaemia. The percentage of participants experi-
encing severe hypoglycaemia was 5.7 % (7/122) with Gla-300
and 9.9 % (12/121) with Gla-100; annualized rates were 0.32
versus 0.22 events per participant-year (Tables S2 and S3).
Body Weight
Change in body weight over 6 months is shown in Figure S2. LS
mean change (standard error) was −0.1 (0.2) kg with Gla-300
and 0.4 (0.2) kg with Gla-100 [LS mean difference −0.6 kg (95
% CI −1.1 to −0.0); p= 0.035].
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Table 1. Baseline characteristics of the randomized population.
Gla-300 Gla-100 All
Characteristic N= 122 N= 121 N= 243
Age, mean (s.d.) years 44.1 (13.9) 46.3 (15.3) 45.2 (14.6)
Male gender, n (%) 56 (45.9) 56 (46.3) 112 (46.1)
Duration of type 1 diabetes, mean (s.d.) years 12.2 (8.6) 13.9 (9.0) 13.0 (8.8)
Body weight, mean (s.d.) kg 63.9 (11.6) 61.0 (11.8) 62.5 (11.7)
BMI, mean (s.d.) kg/m2 23.8 (3.9) 23.2 (3.3) 23.5 (3.6)
HbA1c
mean (s.d.) mmol/mol 64.6 (7.0) 64.7 (8.1) 64.7 (7.5)
mean (s.d.) % 8.06 (0.64) 8.07 (0.74) 8.07 (0.69)
Previous basal insulin type, n (%)
Insulin glargine 110 (90.2) 109 (90.1) 219 (90.1)
NPH insulin 0 1 (0.8) 1 (0.4)
Insulin detemir 12 (9.8) 11 (9.1) 23 (9.5)
Previous basal insulin daily injection number, n (%)
Once daily 84 (68.9) 82 (67.8) 166 (68.3)
Twice daily 38 (31.1) 39 (32.2) 77 (31.7)
Previous daily basal insulin dose, mean (s.d.)
U/kg/day 0.28 (0.12)* 0.30 (0.13)† 0.29 (0.13)
U/day 18.2 (9.2)* 18.5 (9.7)† 18.3 (9.4)
Previous daily mealtime insulin dose, mean (s.d.)
U/kg/day 0.45 (0.18) 0.45 (0.16) 0.45 (0.17)
U/day 29.1 (14.1) 27.2 (11.7) 28.2 (13.0)
Previous daily total insulin dose, mean (s.d.)
U/kg/day 0.73 (0.26)* 0.74 (0.23)† 0.74 (0.24)
U/day 47.1 (21.2)* 45.6 (17.8)† 46.4 (19.6)‡
BMI, body mass index; Gla-100, insulin glargine 100 U/ml; Gla-300, insulin glargine 300 U/ml; HbA1c, glycated haemoglobin; NPH, neutral protamine





A total of 62 % (76/122) and 64 % (78/121) of participants in the
Gla-300 and Gla-100 groups experienced treatment-emergent
AEs. The most commonly reported were infections and infesta-
tions, skin and connective tissue disorders, and gastrointestinal
disorders (Table S4). Treatment-emergent AEs considered
related to treatment were reported by three and two par-
ticipants in the Gla-300 and Gla-100 groups, respectively.
Treatment-emergent SAEs were reported by 2.5 % (3/122 with
Gla-300 and 3/121 with Gla-100) of participants in each group.
One participant receiving Gla-300 permanently discontinued
because of a spinal column stenosis, which was not considered
to be related to study treatment. No injection site reactions
were reported in either group. Hypersensitivity reactions were
reported in 6.6 % (8/122) of participants in the Gla-300 group
and 11.6 % (14/121) of participants in the Gla-100 group; none
were considered to be serious or related to treatment or led
to treatment discontinuation. No deaths occurred in either
treatment group.
Discussion
In this first study of the EDITION programme investigating
outcomes with Gla-300 in a Japanese population with type 1
diabetes treated with basal and mealtime insulin, Gla-300 was
non-inferior to Gla-100 for the primary efficacy measure of
change in HbA1c from baseline to month 6. Consistent with
other EDITION studies (in type 1 and 2 diabetes in larger
worldwide populations) [15–17,19], no between-treatment dif-
ference in HbA1c reduction was observed. This is similar to
results observed in two studies comparing Gla-100 and insulin
degludec in multinational populations, which have also indi-
cated no differences in HbA1c reduction between treatments
[24,25]. Similar results between Gla-300 and Gla-100 were
also found in other glycaemic response parameters, including
laboratory-measured FPG and the percentage of participants
meeting HbA1c and FPG targets, as reported in other EDI-
TION studies [15–19]; however, between-treatment differences
were observed in average pre-dinner, as well as in post-dinner
and bedtime SMPG. In addition, pre-injection SMPG across
this 6-month study was lower with Gla-300 than with Gla-100.
Because daily prandial insulin dose was identical between treat-
ments, it is likely that the difference observed in pre-dinner,
post-dinner and pre-injection SMPG reflects more the differ-
ential effect of Gla-300, with longer PK and PD profiles, versus
Gla-100 [13,14] than the prandial insulin given at lunch and
dinner. This could be particularly relevant for the 30 % of par-
ticipants who had switched from twice-daily basal insulin.
The importance of balancing attainment of glycaemic con-
trol with risk of hypoglycaemia in diabetes management is
reflected by guidelines from the Japanese Diabetes Society,
which include an HbA1c target of <8.0 % for use in individual
Volume 18 No. 4 April 2016 doi:10.1111/dom.12619 379





























































































































Figure 2. Clinical measures across the 6-month study period in the modified intention-to-treat (mITT) population: (A) glycated haemoglobin (HbA1c),
(B) laboratory-measured fasting plasma glucose (FPG), (C) average pre-injection self-monitored plasma glucose (SMPG) profile and (D) daily basal and
mealtime insulin dose. Data are shown as mean± standard error. Gla-100, insulin glargine 100 U/ml; Gla-300, insulin glargine 300 U/ml; BL, baseline; W,
week; M, month; LOCF, last observation carried forward.















































Gla-300 baseline Gla-300 month 6 (LOCF)
Figure 3. Mean eight-point self-monitored plasma glucose (SMPG) profiles at baseline and month 6 (LOCF; modified intention-to-treat population). Data
are shown as mean± standard error. Gla-100, insulin glargine 100 U/ml; Gla-300, insulin glargine 300 U/ml; LOCF, last observation carried forward.
cases when treatment intensification is considered to be dif-
ficult because of the risk of hypoglycaemia [3]; therefore, it is
clinically relevant that the use of Gla-300 in the present study
was associated with a lower risk of hypoglycaemia at any time of
day, and particularly during the night, compared with Gla-100.
The difference in frequency of events was not modest: the annu-
alized rate of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe
hypoglycaemia with Gla-300 was 20 and 34 % lower than that
for Gla-100 for events occurring at any time (24 h) and at night
(00:00–05:59 h), respectively. In addition, the difference in
rates of hypoglycaemia favouring Gla-300 was shown to extend
beyond this predefined nocturnal period and into the daytime
hours. The reduction in hypoglycaemia risk with Gla-300
versus Gla-100 may be attributable to the smoother, more even
PK and PD profiles of Gla-300 [13], and the low within-day
variability in Gla-300 exposure [12]. It is notable that the
difference between treatment groups in the occurrence of
hypoglycaemia was seen most prominently between 06:00 and
08:59 h (Figure S1). This is potentially attributable to ascertain-
ment bias, as participants may have been more likely to check
their plasma glucose during this time than during the night.
The lower frequency of nocturnal hypoglycaemia in the
Gla-300 group was observed throughout the study period
across the different definitions, but was particularly apparent
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Confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia
Confirmed (<3.0 mmol/l [<54 mg/dl]) or severe hypoglycaemia
Baseline to month 6 0.80 0.65 to 0.98 0.66 0.48 to 0.92
Baseline to week 8 0.69 0.56 to 0.86 0.58 0.41 to 0.84
Week 9 to month 6 0.86 0.69 to 1.07 0.71 0.49 to 1.01
Baseline to month 6 0.81 0.60 to 1.11 0.49 0.31 to 0.76
Baseline to week 8 0.72 0.53 to 0.99 0.37 0.22 to 0.64
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Confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia
Confirmed (<3.0 mmol/l [<54 mg/dl]) or severe hypoglycaemia
Baseline to month 6 0.99 0.95 to 1.04 0.85 0.73 to 0.99
Baseline to week 8 0.91 0.84 to 0.99 0.71 0.56 to 0.91
Week 9 to month 6 1.01 0.95 to 1.08 0.84 0.70 to 1.00
Baseline to month 6 0.87 0.78 to 0.96 0.69 0.52 to 0.91
Baseline to week 8 0.74 0.62 to 0.87 0.60 0.40 to 0.89



























































(95 % CI: 0.65 to 0.98)
p=0.028
 Rate ratio: 0.66






















































































Figure 4. Occurrence of confirmed or severe hypoglycaemic events during the 6-month study period (safety population): (A) cumulative mean number of
confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe events per participant at any time (24 h) and (B) events per participant-year; (C) cumulative mean number
of nocturnal (00:00–05:59 h) confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe events per participant and (D) events per participant-year; (E) ratio of event
rates and (F) relative risk, during the night (00:00–05:59 h) and at any time (24 h). CI, confidence interval.
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during the first 8 weeks, when most of the increase in basal
insulin dose occurred. This is consistent with results from a
multinational population of people with type 1 diabetes in
EDITION 4, in which a 31 % lower rate of nocturnal con-
firmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia
was observed in the first 8 weeks with Gla-300 versus Gla-100
(although in EDITION 4 the between-treatment difference was
not maintained over the whole study period); however, the sig-
nificantly lower rate of hypoglycaemia at any time of day (24 h)
with Gla-300 versus Gla-100 in the present study is not reflected
in EDITION 4, where no between-treatment differences in rates
at any time of day were observed [16]. These contrasting results
may be explained in part by differences in diet and lifestyle
between the populations, which could alter the effect of exoge-
nous insulin, and hence, risk of hypoglycaemia. In addition, half
of the participants in EDITION 4 received their basal insulin
dose in the morning and half in the evening, whereas all of
the participants in the present study received their basal insulin
dose during the evening. Significantly lower rates of nocturnal
confirmed or severe hypoglycaemia were also observed with
Gla-300 than with Gla-100 in the present study at the more
stringent threshold [<3.0 mmol/l (<54 mg/dl)]. These are of
particular interest in type 1 diabetes, in which the biochemi-
cal mechanisms that protect against hypoglycaemia are com-
promised [26]. Similar results were observed in a continuous
glucose monitoring study of people with type 1 diabetes, in
which the annualized rate of similarly defined hypoglycaemia
was lower with Gla-300 than with Gla-100 [20].
As expected, given the wealth of clinical experience on the
safety of Gla-100 [27], Gla-300 was well tolerated with no
reported injection site reactions or safety concerns. There was
a small but statistically significant difference in body weight
change between groups; however, the reason for this is not
known. A slightly higher Gla-300 dose was required, which was
probably related to a lower 24-h exposure versus Gla-100 at
equal doses, which may be attributable to increased residence
time in, and slower absorption from, the smaller subcutaneous
depot. Despite the slightly higher dose, fewer hypoglycaemic
events and smaller weight changes were experienced by par-
ticipants receiving Gla-300 versus Gla-100, showing that there
were no clinical implications in terms of safety, consistent with
other EDITION studies [15–19].
To date, the efficacy and safety of newer long-acting insulin
analogues in people with type 1 diabetes in Japan has only been
reported for one other randomized controlled study, which
evaluated insulin degludec versus insulin detemir adminis-
tered once daily at bedtime in 66 adults with type 1 diabetes
[28]. The study showed that the use of insulin degludec was
associated with similar glycaemic control and a lower risk of
nocturnal hypoglycaemia versus insulin detemir; however, the
differences in study design and methodology between these
two studies, including the different control insulins, limit direct
comparisons.
The present study extends previous observations regarding
efficacy and safety of Gla-300 in type 1 diabetes from multi-
national populations [16,20] to Japanese adults. No difference
in glycaemic control with Gla-300 and Gla-100 was confirmed,
together with greater relative reductions in hypoglycaemic
event rates with Gla-300. The strengths of the present study
include adequate statistical power to answer the questions
posed, careful supervision of basal insulin titration and iden-
tification of hypoglycaemic events, and very high participant
retention. The main study limitation was the open-label design,
which was unavoidable as different injection volumes and injec-
tion pens were required for Gla-300 and Gla-100.
In conclusion, in Japanese adults with type 1 diabetes using
basal and mealtime insulin, there was no between-treatment
difference in HbA1c reduction over 6 months of treatment.
Average pre-injection SMPG was significantly lower with
Gla-300 versus Gla-100 at month 6. Less hypoglycaemia was
observed with Gla-300, particularly at night, and even in the
first 8 weeks of treatment, versus Gla-100.
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